Creo Medical Group (LON:CREO) Insider Craig Jonathan Gulliford Purchases 6,250 Shares of Stock

Creo Medical Group PLC (LON:CREO) insider Craig Jonathan Gulliford bought 6,250 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was bought at an average price of GBX 14 per share, for a total transaction of £875.

Creo Medical Group Stock Performance

Creo Medical Group stock opened at GBX 14.38 on Tuesday. The company has a debt-to-equity ratio of 8.20, a quick ratio of 2.19 and a current ratio of 3.22. The company has a market capitalization of £69.83 million, a PE ratio of 14.38 and a beta of 1.62. The company has a 50 day moving average price of GBX 13.22 and a 200-day moving average price of GBX 12.93. Creo Medical Group PLC has a fifty-two week low of GBX 9.52 and a fifty-two week high of GBX 18.50.

Creo Medical Group (LON:CREO) last announced its quarterly earnings data on Friday, May 22nd. The company reported GBX (0.04) earnings per share (EPS) for the quarter. The firm had revenue of GBX 600 million during the quarter. Creo Medical Group had a return on equity of 9.56% and a net margin of 88.33%. As a group, equities analysts forecast that Creo Medical Group PLC will post -10.0800005 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Shore Capital Group restated a “house stock” rating and set a GBX 40 price target on shares of Creo Medical Group in a research note on Monday, June 29th.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy.

The Company’s vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes.